title: Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer.
abstract: The anti-angiogenic, monoclonal antibody bevacizumab, in combination with chemotherapy, is proven to prolong survival in metastatic colorectal cancer. Recent data demonstrate that combining bevacizumab with widely used oxaliplatin-containing chemotherapy regimens is a promising strategy for further improving patient outcomes.
authors: Division of Oncology, Department of Medicine I and Cancer Center, Medical University Vienna, Austria. werner.scheithauer@meduniwien.ac.at
authors: Werner
authors: W
authors: Scheithauer
authors: Wolff
authors: W
authors: Schmiegel
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D000077150:Oxaliplatin
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab